Targovax ASA moves share listing to Oslo Børs
Oslo, Norway, 23 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that its shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. The Company was previously listed on Oslo Axess, a regulated and licensed market under the auspices of the Oslo Stock Exchange. Since listing the shares of Targovax on Oslo Axess in July 2016, the Company has achieved several milestones, including: · Encouraging top line two-year